• Pharvaris’ third-quarter 2026 loss widened 28% year over year to €47.4 million.
• General and administrative expenses jumped 81% to €17.7 million, while research and development spending rose 9% to €32.4 million.
• Cash and cash equivalents fell to €283 million at September 30, 2026.
• The FDA is reviewing deucrictibant IR for on-demand treatment of HAE attacks, with an April 23, 2027, decision deadline.
• A U.S. application for deucrictibant XR to prevent bradykinin-mediated angioedema attacks remains on track for submission in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-456847), on November 12, 2026, and is solely responsible for the information contained therein.